Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease - PubMed (original) (raw)
Review
Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease
Linda L Humphrey et al. Ann Intern Med. 2002.
Free article
Abstract
Purpose: To evaluate the value of hormone replacement therapy (HRT) in the primary prevention of cardiovascular disease (CVD) and coronary artery disease (CAD).
Data sources: MEDLINE and Cochrane databases were searched for all primary prevention studies reporting CVD or CAD incidence, mortality, or both in association with HRT; reference lists, letters, editorials, and reviews were also reviewed.
Data extraction: All studies were reviewed, abstracted, and rated for quality.
Study selection: Only studies of good or fair quality, according to U.S. Preventive Services Task Force (USPSTF) criteria, were included in the detailed review and meta-analysis.
Data synthesis: The summary relative risk with any HRT use was 0.75 (95% credible interval [CrI], 0.42 to 1.23) for CVD mortality and 0.74 (CrI, 0.36 to 1.45) for CAD mortality. The summary relative risk with any use was 1.28 (CrI, 0.86 to 2.00) for CVD incidence and 0.87 (CrI, 0.62 to 1.21) for CAD incidence. Further analysis of studies adjusting for socioeconomic status, as well as other major CAD risk factors, showed a summary relative risk of 1.07 (CrI, 0.79 to 1.48) for CAD incidence associated with any HRT use. Similar results were found when the analysis was stratified by studies adjusting for alcohol consumption, exercise, or both, in addition to other major risk factors, suggesting confounding by these factors.
Conclusions: This meta-analysis differs from previous meta-analyses by evaluating potential explanatory variables of the relationship between HRT, CVD, and CAD. The adjusted meta-analysis is consistent with recent randomized trials that have shown no benefit in the secondary or primary prevention of CVD events. A valid answer to the role of HRT in the primary prevention of CVD will best come from randomized, controlled trials.
Comment in
- Postmenopausal hormone replacement therapy: how could we have been so wrong?
Laine C. Laine C. Ann Intern Med. 2002 Aug 20;137(4):290. doi: 10.7326/0003-4819-137-4-200208200-00015. Ann Intern Med. 2002. PMID: 12186521 No abstract available. - Postmenopausal hormone replacement therapy.
Chausmer AB. Chausmer AB. Ann Intern Med. 2003 Apr 15;138(8):687-8; author reply 688-9. doi: 10.7326/0003-4819-138-8-200304150-00027. Ann Intern Med. 2003. PMID: 12693901 No abstract available. - Postmenopausal hormone replacement therapy.
Meyerson SJ. Meyerson SJ. Ann Intern Med. 2003 Apr 15;138(8):687; author reply 688-9. doi: 10.7326/0003-4819-138-8-200304150-00026. Ann Intern Med. 2003. PMID: 12693902 No abstract available. - Postmenopausal hormone replacement therapy.
Grodstein F, Manson JE, Stampfer MJ. Grodstein F, et al. Ann Intern Med. 2003 Apr 15;138(8):688; author reply 688-9. doi: 10.7326/0003-4819-138-8-200304150-00028. Ann Intern Med. 2003. PMID: 12693903 No abstract available. - Postmenopausal hormone replacement therapy and cardiovascular disease.
Ritterband AB, Jaffe IA. Ritterband AB, et al. Ann Intern Med. 2004 Mar 2;140(5):402. doi: 10.7326/0003-4819-140-5-200403020-00020. Ann Intern Med. 2004. PMID: 14996686 No abstract available.
Similar articles
- Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease [Internet].
Humphrey LL, Takano LMA, Chan BKS. Humphrey LL, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 Aug. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 Aug. PMID: 20722105 Free Books & Documents. Review. - Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Whitlock EP, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 13-05193-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 13-05193-EF-1. PMID: 26491756 Free Books & Documents. Review. - Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Wolff T, Miller T, Ko S. Wolff T, et al. Ann Intern Med. 2009 Mar 17;150(6):405-10. doi: 10.7326/0003-4819-150-6-200903170-00009. Ann Intern Med. 2009. PMID: 19293073 Review. - Hormone replacement therapy and cardioprotection: the end of the tale?
Rosano GM, Vitale C, Silvestri A, Fini M. Rosano GM, et al. Ann N Y Acad Sci. 2003 Nov;997:351-7. doi: 10.1196/annals.1290.038. Ann N Y Acad Sci. 2003. PMID: 14644842 Review. - Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].
LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. LeBlanc EL, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. PMID: 30354042 Free Books & Documents. Review.
Cited by
- GPR30 Alleviates Pressure Overload-Induced Myocardial Hypertrophy in Ovariectomized Mice by Regulating Autophagy.
Zhang S, Ma J, Wang X, Zhao D, Zhang J, Jiang L, Duan W, Wang X, Hong Z, Li Z, Liu J. Zhang S, et al. Int J Mol Sci. 2023 Jan 4;24(2):904. doi: 10.3390/ijms24020904. Int J Mol Sci. 2023. PMID: 36674423 Free PMC article. - Sex hormones and the risk of cardiovascular disease and mortality in male and female patients with chronic kidney disease: A systematic review and meta-analysis.
Oh ES, Steele CN, You Z, Nowak KL, Jovanovich AJ. Oh ES, et al. Physiol Rep. 2022 Nov;10(22):e15490. doi: 10.14814/phy2.15490. Physiol Rep. 2022. PMID: 36394074 Free PMC article. - Menopausal hormone therapy and women's health: An umbrella review.
Zhang GQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, Talibov M, Zhang J, Hawrylowicz CM, Lumsden MA, Critchley H, Sheikh A, Lundbäck B, Lässer C, Kankaanranta H, Lee SH, Nwaru BI. Zhang GQ, et al. PLoS Med. 2021 Aug 2;18(8):e1003731. doi: 10.1371/journal.pmed.1003731. eCollection 2021 Aug. PLoS Med. 2021. PMID: 34339416 Free PMC article. Review. - Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women.
Cetin EC, Guven S, Sal H, Guvendag Guven ES, Mentese A. Cetin EC, et al. Prz Menopauzalny. 2021 Jun;20(2):76-80. doi: 10.5114/pm.2021.106089. Epub 2021 May 23. Prz Menopauzalny. 2021. PMID: 34321985 Free PMC article. - The 2020 Menopausal Hormone Therapy Guidelines.
Academic Committee of the Korean Society of Menopause; Lee SR, Cho MK, Cho YJ, Chun S, Hong SH, Hwang KR, Jeon GH, Joo JK, Kim SK, Lee DO, Lee DY, Lee ES, Song JY, Yi KW, Yun BH, Shin JH, Chae HD, Kim T. Academic Committee of the Korean Society of Menopause, et al. J Menopausal Med. 2020 Aug;26(2):69-98. doi: 10.6118/jmm.20000. J Menopausal Med. 2020. PMID: 32893509 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous